A Clinicopathologic and Molecular Study of BRCA1/2-mutated Pancreatic Ductal Adenocarcinoma

被引：0
|
作者：
Li, Hongjie [1 ]
Gibson, Joanna [1 ]
Jain, Dhanpat [1 ]
Finberg, Karin [1 ]
Walther, Zenta [1 ]
Zhong, Minghao [1 ]
机构：
[1] Yale Sch Med, New Haven, CT USA
来源：
MODERN PATHOLOGY | 2021年 / 34卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
877
引用
收藏
页码：1050 / 1051
页数：2
相关论文
共 50 条
  • [1] A Clinicopathologic and Molecular Study of BRCA1/2-mutated Pancreatic Ductal Adenocarcinoma
    Li, Hongjie
    Gibson, Joanna
    Jain, Dhanpat
    Finberg, Karin
    Walther, Zenta
    Zhong, Minghao
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 1050 - 1051
  • [2] GENOMICS OF BRCA1/2-MUTATED BREAST CANCERS
    Jonkers, J.
    CELLULAR ONCOLOGY, 2010, 32 (03) : 162 - 162
  • [3] Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma
    Seeber, Andreas
    Zimmer, Kai
    Kocher, Florian
    Puccini, Alberto
    Xiu, Joanne
    Nabhan, Chadi
    Elliott, Andrew
    Goldberg, Richard M.
    Grothey, Axel
    Shields, Anthony F.
    Battaglin, Francesca
    El-Deiry, Wafik S.
    Philip, Philip A.
    Marshall, John L.
    Hall, Michael
    Korn, W. Michael
    Lenz, Heinz-Josef
    Wolf, Dominik
    Feistritzer, Clemens
    Spizzo, Gilbert
    ESMO OPEN, 2020, 5 (06)
  • [4] Molecular profiling comparison of BRCA1/2-mutated and BRCA1/2 non-mutated triple-negative breast cancer (TNBC)
    Arguello, D.
    Abbott, B.
    Reddy, S.
    Gatalica, Z.
    Obeid, E.
    Goldstein, L.
    CANCER RESEARCH, 2016, 76
  • [5] Responses to carboplatin in BRCA1/2-mutated breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2018, 19 (07): : E337 - E337
  • [6] Use of PARP Inhibitors in BRCA1/2-mutated Pancreatic Carcinoma in Reality: a retrospective Analysis
    Zhang, D.
    Amin, S.
    Li, W.
    Joo, S.
    Adeboyeje, G.
    DeArbeloa, P.
    Petricoin, E. F.
    Blais, E. M.
    Pishvaian, M. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 225 - 225
  • [7] Secondary BRCA1/2 mutations are associated with platinum resistance in BRCA1/2-mutated ovarian carcinomas
    Norguist, B.
    Taniguchi, T.
    Wurz, K.
    Karlan, B.
    Villegas, E.
    Sakai, W.
    Swisher, E.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : 594 - 594
  • [8] BRCA1/2 reversion mutations as a mechanism of acquired drug resistance in BRCA1/2-mutated cancers
    Taniguchi, Toshiyasu
    CANCER SCIENCE, 2023, 114 : 260 - 260
  • [9] The Role of BRCA1/2-Mutated Tumor Microenvironment in Breast Cancer
    Miklikova, Svetlana
    Trnkova, Lenka
    Plava, Jana
    Bohac, Martin
    Kuniakova, Marcela
    Cihova, Marina
    CANCERS, 2021, 13 (03) : 1 - 17
  • [10] BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma
    Blair, Alex B.
    Groot, Vincent P.
    Gemenetzis, Georgios
    Wei, Jishu
    Cameron, John L.
    Weiss, Matthew J.
    Goggins, Michael
    Wolfgang, Christopher L.
    Yu, Jun
    He, Jin
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 226 (04) : 630 - 637
12345